User:Ahmed Zaghw: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
(Replaced content with "Ahmed Zaghw is a medical education fellow at PERFUSE Study Group. He graduated from the school of medicine at Ain Shams University, Cairo. ==Education== ==Work Experien...")
Line 1: Line 1:
[[Idiopathic interstitial pneumonia]]
Ahmed Zaghw is a medical education fellow at PERFUSE Study Group. He graduated from the school of medicine at Ain Shams University, Cairo.


[[Sepsis resident survival guide]]
==Education==


[[Resident survival guide topics]]


[[MICU Intern's survival guide sepsis]]
==Work Experience==


[[Interstitial lung disease]]


==Research Experience==


{{Family tree/start}}
{{Family tree | | | | A01 |-|-|-| A02 | |A01= Stable| A02= Unstable}}
{{Family tree/end}}


==Languages==


{{Family tree/start}}
*English: Fluent in speaking and writing
{{Family tree | | | | A01 | | | |A01= Box 1 in Row 1}}
{{Family tree | | | | |!| | | | | }}
{{Family tree | | | | B01 | | | |B01= Box 2 in Row 2}}
{{Family tree | |,|-|-|^|-|-|.| | }}
{{Family tree | C01 | | | | C02 |C01= Box 3 in Row 3| C02= Box 4 in Row 4}}
{{Family tree/end}}


*Arabic: Mother tongue


{{Family tree/start}}
*Deutsch: Very good in speaking and writing
{{Family tree | | C01 | | | | | | C02 | |C01= Ahmed| C02= Dzenana}}
{{Family tree/end}}


==Contact Information==


{|class="wikitable"
E-mail address: ahmedzaghw@wikidoc.org
|lolo||lolo2||lolo3
|-
|koko1||koko2||koko3
|-
|}
 
---
{|class="wikitable" width="80%"
|lolo||lolo2||lolo3
|-
|koko1||koko2||koko3
|-
|}
 
----
{|class="wikitable"width="80%"
|-
| colspan="1" style="text-align:center; background:"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]]
|-
| bgcolor=""|<nowiki>"</nowiki>'''1. '''High-intensity statin therapy should be initiated or continued as first-line therapy in women and men ≤75 years of age who have clinical ASCVD, unless contraindicated.''([[ACC AHA guidelines classification scheme#Classification of Recommendations|Level of Evidence: A]])''<nowiki>"</nowiki>
|-
| bgcolor=|<nowiki>"</nowiki>'''2. '''In individuals with clinical ASCVD* in whom high-intensity statin therapy would otherwise be used, when high-intensity statin therapy is contraindicated† or when characteristics predisposing to statin-associated adverse effects are present, moderate-intensity statin should be used as the second option if tolerated.''([[ACC AHA guidelines classification scheme#Classification of Recommendations|Level of Evidence: A]])''<nowiki>"</nowiki>
|-
|}
 
 
{|style="width:80%; height:100px" border="1"
|style="height:100px"; style="width:25%" border="1" bgcolor="LightSteelBlue" |'''Cardiovascular'''
|style="height:100px"; style="width:75%" border="1" bgcolor="Beige" | No underlying causes
|-
|bgcolor="LightSteelBlue"| '''Chemical/Poisoning'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Dental'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Dermatologic'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Drug Side Effect'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Ear Nose Throat'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Endocrine'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Environmental'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Gastroenterologic'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Genetic'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Hematologic'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Iatrogenic'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Infectious Disease'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Musculoskeletal/Orthopedic'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Neurologic'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Nutritional/Metabolic'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Obstetric/Gynecologic'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Oncologic'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Ophthalmologic'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Overdose/Toxicity'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Psychiatric'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Pulmonary'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Renal/Electrolyte'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Rheumatology/Immunology/Allergy'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Sexual'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Trauma'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Urologic'''
|bgcolor="Beige"| No underlying causes
|-
|-bgcolor="LightSteelBlue"
| '''Miscellaneous'''
|bgcolor="Beige"| No underlying causes
|-
|}
<table>
{|class="wikitable" border="1" style="text-align:center; width:600px;"
|-style="background:#CDC9C9"
| Risk category
| LDL goal, mg/dL
|Non-HDL goal, mg/dL
|-
| CHD and CHD risk equivalent (10 year risk for CHD is >20%)
| < 100
| < 130
|-
| Multiple (2+) risk factor (10 year risk for CHD is <20%)
| < 130
| < 160
|-
| 0-1 risk factors
| < 160
| < 190
|-
|}
 
ATP III LDL cholesterol and Non-HDL cholesterol goals <ref name="pmid11368702">{{cite journal| author=Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults| title=Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). | journal=JAMA | year= 2001 | volume= 285 | issue= 19 | pages= 2486-97 | pmid=11368702 | doi= | pmc= |url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11368702 }} </ref>
 
 
{|class="wikitable" width="80%"
|-
| colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]]
|-
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''1. '''Individuals with LDL–C ≥190 mg/dL or triglycerides ≥500 mg/dL should be evaluated for secondary causes of hyperlipidemia.''([[ACC AHA guidelines classification scheme#Classification of Recommendations|Level of Evidence: B]])''<nowiki>"</nowiki>
|-
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''2. '''Adults ≥21 years of age with primary LDL–C ≥190 mg/dL should be treated with statin therapy (10-year ASCVD risk estimation is not required): <BR>
* Use high-intensity statin therapy unless contraindicated. <BR>
 
* For individuals unable to tolerate high-intensity statin therapy, use the maximum tolerated statin intensity.''([[ACC AHA guidelines classification scheme#Classification of Recommendations|Level of Evidence: B]])''<nowiki>"</nowiki>
|-
|}
 
==References==
{{Reflist|2}}

Revision as of 07:26, 27 November 2013

Ahmed Zaghw is a medical education fellow at PERFUSE Study Group. He graduated from the school of medicine at Ain Shams University, Cairo.

Education

Work Experience

Research Experience

Languages

  • English: Fluent in speaking and writing
  • Arabic: Mother tongue
  • Deutsch: Very good in speaking and writing

Contact Information

E-mail address: ahmedzaghw@wikidoc.org

Retrieved from "https://www.wikidoc.org/index.php?title=User:Ahmed_Zaghw&oldid=915314"